和黄医药(00013.HK)“沃瑞沙”治疗非小细胞肺癌新适应症上市申请获批

阿斯达克财经
Jan 14, 2025

和黄医药(00013.HK) 宣布,与阿斯利康(AZN.US)  共同开发的口服间质-上皮转化因子(MET)酪氨酸激酶抑制剂(TKI)“沃瑞沙”,用于治疗具有MET外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者,新适应症上市申请已获中国国家药监局批准。国家药监局亦将早前沃瑞沙在经治患者中的附条件批准转为常规批准,意味着沃瑞沙在中国的新适应症将扩展至同时涵盖初治和经治患者。和黄医药研发负责人兼...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10